The MATRiX trial: A multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1–refractory Merkel cell carcinoma.

Authors: Rashmi Bhakuni, Evan Thomas Hall, George Ansstas, Shailender Bhatia, Andrew Scott Brohl, Melissa Amber Burgess, Maya Dimitrova, Ling Gao, Jeffrey Joseph Ishizuka, Evan J. Lipson, Jose Lutzky, Ann W. Silk, Jina Yun, Isaac Brownell, Judy Murray, Yvonne Marie Mowery, Ted Gooley, Steven Gore, Suzanne Louise Topalian, Paul Nghiem

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps9598

Source: Full article

---

Abstract

TPS9598